Introduction
============

Although incidence of gastric cancer has fallen markedly in the recent years, it still remains one of the most common cancers. Gastric cancer is the second leading cause of cancer-related death, and the 5-year survival was 28% in 2014.[@b1-ott-10-2155] Most of the patients are found to be at locally advanced stage by the time of diagnosis, which consequently leads to poorer quality of life and shorter survival. Although some prognostic markers such as the modified Glasgow Prognostic Score,[@b2-ott-10-2155],[@b3-ott-10-2155] neutrophil--lymphocytes ratio (NLR),[@b4-ott-10-2155],[@b5-ott-10-2155] and platelet--lymphocytes ratio[@b5-ott-10-2155] have already been demonstrated to be valuable in gastric cancer, exploration for the serum albumin--globulin ratio (AGR) has not been performed yet. There is a need to explore the association between the prognosis of gastric cancer and AGR.

Besides some other inflammatory proteins (such as C-reactive protein, interleukins, and tumor necrosis factors),[@b6-ott-10-2155] human total protein contains two main constituents, serum albumin (35--55 g/L) and globulin (20--35 g/L). Serum albumin has been mentioned to be associated with the nutrition status and the progression of several diseases.[@b7-ott-10-2155] Previous studies have shown that low albumin level is associated with the poor prognosis of several cancers, such as gastric,[@b8-ott-10-2155] colorectal,[@b9-ott-10-2155]--[@b12-ott-10-2155] pancreatic,[@b13-ott-10-2155] lung,[@b14-ott-10-2155] ovarian cancers,[@b14-ott-10-2155],[@b15-ott-10-2155] and so on. Albumin and globulin play an important role in immunity and inflammation; they are valuable predictors in the progress of diseases.[@b16-ott-10-2155] However, both the chemical predictors are easily affected by other factors such as dehydration and edema, which influence their value of efficiency and accuracy. Thus, our study attempted to explore a reliable index combined by serum albumin and globulin, by putting these two indexes together. The AGR ratio was calculated using the equation: albumin/(total protein − albumin). To the best of our knowledge, we are the first to explore the association between AGR and the prognosis of gastric cancer.

Patients and methods
====================

Ethics statement
----------------

This study complied with the standards of the Declaration of Helsinki and was approved by the Ethical Committees of Sun Yat-sen University Cancer Center. Patients who signed informed consent were included.

Study population and data collection
------------------------------------

Patients hospitalized between June 2005 and December 2012 were enrolled in this study, all of whom were treated at the Department of Gastropancreatic Surgery, Sun Yat-sen Cancer Center, Guangzhou, People's Republic of China. A total of 507 cases of this cohort matched our inclusion and exclusion criteria. The inclusion criteria were as follows: 1) patients with pathologically or histologically proven gastric cancer; 2) Patients with no acute or chronic inflammation, immune disease, hematological disease, liver disease, or concomitant cancer, which could influence the level of the proteins; 3) Patients for whom complete biochemistry index and blood data were available before surgery, chemotherapy, and radiotherapy; 4) All the patients who underwent D2 curative resection at last (thus, patients in stage IV were excluded); 5) Patients who were staged according to the tumor node metastasis criteria (American Joint Committee on Cancer \[AJCC\] criteria seventh edition).[@b17-ott-10-2155]

Various clinical variables were investigated, including age, sex, tumor size, differentiated type, the depth of invasion, lymph node status, AJCC stage, location, tumor markers, and laboratory variables ([Table 1](#t1-ott-10-2155){ref-type="table"}). The depth of invasion (T), the lymph node status (N), the presence of metastasis (M), and the AJCC stage for every patient were obtained from the data in our hospital cancer registry.[@b17-ott-10-2155] For survival analysis, we divided the patients into two groups according to the best cutoff value obtained by the software X-tile software Version 3.6.1 (Yale University School of Medicine, New Haven, CT, USA). The low AGR group comprised 440 patients and had lower AGR value, and the high AGR group comprised 67 patients and had higher low AGR value (\<1.93). Survival status of each group was analyzed, and the primary end point was death due to any causes. The follow-up ended in December 2014, and the data were obtained from our hospital cancer registry. The follow-up duration was defined as the time between the day when the operation was performed until the day cancer recurred or the patient died of any other causes, and overall survival time was defined as the time between the operation and death or the last follow-up.

X-tile analysis
---------------

The X-tile software Version 3.6.1 (Yale University School of Medicine) was used to discover the optimal cutoff points of the AGR based on the outcome. X-plots generated by the software were used to evaluate the expression level of the AGR. The assessment of statistical significance was performed by corrected *P*-value, which was produced by log-rank test ([Figure 1](#f1-ott-10-2155){ref-type="fig"}).[@b18-ott-10-2155]

Statistical analysis
--------------------

All statistical analyses were performed by the software Statistical Package for Social Sciences Version 19.0 (SPSS, Chicago, IL). A result was considered statistically significant only when the *P*-value was \<0.05. The two AGR groups were analyzed using the chi-square test for categorical variables and the Kruskal--Wallis test for continuous variables. The continuous variables were presented as mean ± SD and categorical variables were presented as frequency. We analyzed the differences of survival status between each AGR group. Furthermore, in case of the influence of low serum albumin and short-term mortality, differences of post-6-month survivors and patients with normal serum albumin (albumin ≥35 g/L) were also analyzed, in which the Kaplan--Meier curves and log-rank test were used. Additional analysis was done to explore the association between calculated globulin and prognosis. All the promising predictors in [Table 1](#t1-ott-10-2155){ref-type="table"} were analysed with a univariate Cox proportional hazards model separately. The variable would enter a multivariate analysis if it was statistically and clinically significant. Entry selection was used to exclude the factors that did not make much difference to this Cox model and to add new meaningful variables. Subsequently, survival analysis was performed by these professional methods and principles.

Results
=======

Mean age of our study population was 58.8 years, 348 (68.6%) were males, 100 (19.7%) were well/moderately differentiated, and 135 (26.6%) had tumor size \<6 cm^2^. The number of patients with upper, middle, and lower tumor were 246, 80, and 181, respectively, and 59, 101, 347 for stage I, II, III patients. Inflammation markers (eg, neutrophil count and C-reactive protein) in the low AGR group were signifi-cantly higher than those in the high AGR group; however, hemoglobin count was higher in the high AGR group and albumin was lower in the low AGR group ([Table 1](#t1-ott-10-2155){ref-type="table"}).

The mean survival time for each group was, for the low AGR group 36.62 months (95% CI \[confidence interval\]: 33.92--39.32), and for the high AGR group 48.95 months (95% CI: 41.93--55.96; *P*=0.003). Patients in the high AGR group (AGR ≥1.93) had a significantly lower 5-year mortality in comparison with the low AGR group (AGR \<1.93; 52.4% vs 78.5%, *P*=0.003). The high AGR group showed obviously better overall survival than the low AGR group according to Kaplan--Meier curves (*P*=0.003; [Figure 2A](#f2-ott-10-2155){ref-type="fig"}). Serum albumin (39.8±4.7 vs 42.7±3.5, *P*=0.012) and AGR values (AGR \<1.93 vs AGR ≥1.93) in the high AGR group were clearly higher than that of the low AGR group, while globulin (26.8±4.2 vs 20.7±2.9) in the low AGR group was higher than that of the high AGR group. Furthermore, when we excluded the patients who died in the first 6 months of follow-up, the 5-year mortality rates were 244/392 (62.2%) and 28/64 (43.8%) for the low and high AGR groups, respectively (*P*=0.011; [Figure 2B](#f2-ott-10-2155){ref-type="fig"}). The same conclusion was drawn in the patients whose serum albumin was ≥35 g/L, and the 5-year mortality rates for the low AGR group and the high AGR group were 224/373 (60.0%) and 29/66 (43.9%, *P*=0.009; [Figure 2C](#f2-ott-10-2155){ref-type="fig"}), respectively. When we divided the population into two groups according to the calculated globulin, the low globulin group showed better survival in both the total population (*P*=0.005; [Figure 3A](#f3-ott-10-2155){ref-type="fig"}) and the patients whose serum albumin was ≥35 g/L (*P*\<0.001; [Figure 3B](#f3-ott-10-2155){ref-type="fig"}). Association between each variable and overall survival is presented in [Table 2](#t2-ott-10-2155){ref-type="table"}, in which univariate Cox regression was performed. [Table 2](#t2-ott-10-2155){ref-type="table"} shows that age, tumor size, node stage, AJCC stage, T stage, White blood cell (WBC) count, globulin count, neutrophil count, and C-reactive protein count were higher in those patients who had higher mortality rates. Patients with higher total protein, albumin count, lymphocyte count, and hemoglobin count shared lower mortality rates. Lower mortality was fairly apparent in patients with high AGR value (*P*=0.003). In addition, the hazard ratio of the patients in the low AGR group increased by 1.755 (*P*=0.003) when compared with the high group ([Table 2](#t2-ott-10-2155){ref-type="table"}).

Variables associated with overall survival in the univariate Cox regression model were included in the Cox proportional hazard multivariate model. In consideration of the high degree of correlation between AJCC stage and T/N stage, two separate analyses were performed. Model 1 (including variables such as age, location, AJCC stage, NLR, and AGR) and Model 2 (including variables such as age, location, N stage, T stage, NLR, and AGR) showed that AGR is an independent predictor of prognosis in gastric cancer patients ([Table 3](#t3-ott-10-2155){ref-type="table"}), with HR value even higher than NLR (Model 1: 1.374 vs 1.062 and Model 2: 1.489 vs 1.072).

Discussion
==========

Albumin, which is one of the proteins produced in the liver, has been shown to maintain the osmotic pressure and act as a free radical scavenger.[@b19-ott-10-2155] Albumin was useful in evaluating nutrition status, disease regression, and prognosis in patients.[@b19-ott-10-2155],[@b20-ott-10-2155] For example, hypoalbuminemia usually implied situation such as malnutrition, chronic inflammation, nephritic syndrome, and liver disease suppress albumin synthesis.[@b21-ott-10-2155] Additionally, albumin was shown to have a more important role in chronic inflammation than malnutrition.[@b22-ott-10-2155],[@b23-ott-10-2155] Circulating albumin has been demonstrated to play an important role in the anticancer procedure by several mechanisms, including its antioxidant function on many carcinogens, its effect on homeostasis of calcium and steroid hormone, and its negative role in cancer cell lines.[@b19-ott-10-2155],[@b20-ott-10-2155] Prior studies have shown that patients with lower albumin usually had worse prognosis. In 2014, Isik et al[@b8-ott-10-2155] indicated that a level of preoperative serum albumin \<35 g/L predicted poor prognosis for resectable gastric cancer patients. Similar results could be seen in many other cancers, including breast,[@b24-ott-10-2155] lung,[@b14-ott-10-2155] ovarian,[@b25-ott-10-2155] and colorectal cancers.[@b16-ott-10-2155] In this study, we also found that patients in the low albumin group had worse survival in comparison to those in the high group.

Similarly, high nonalbumin level was demonstrated to be associated with mortality in some cancers. Inflammatory proteins (such as C-reactive protein, interleukins, and tumor necrosis factors), which are calculated globulins, increase when inflammation occurs and can predict the occurrence of inflammation. Chronic inflammation markers take an important part in promoting tumor development, proliferation, progression, development, metastasis, and recurrence.[@b22-ott-10-2155],[@b26-ott-10-2155] As a chronic inflammation marker, globulin could reflect cumulative exposure to various proinflamma-tory cytokines such as interleukins (IL), particularly IL-6 and IL-1b, and tumor necrosis factor-α.[@b22-ott-10-2155] Previous studies have shown that the expression of globulin contributes to the occurrence of various cancers, such as ovarian,[@b27-ott-10-2155] prostate,[@b28-ott-10-2155] and breast cancers.[@b29-ott-10-2155],[@b30-ott-10-2155]

To our knowledge, chronic inflammation is a critical contributor to tumor growth, development progression, angiogenesis, metastasis, and recurrence. Inflammatory cells could act as powerful tumor promoters with inflammatory cytokines being released and the formation of an inflammatory microenvironment.[@b31-ott-10-2155] We suppose that the changes in the expression levels of globulin and albumin may be a significant markers in reflecting such chronic inflammation, which influence the prognosis of gastric cancer.

Recently, AGR, combining nonalbumin and serum albumin, has been given much attention. For instance, Du et al[@b32-ott-10-2155] proposed that low level of AGR predicted poor survival of patients with undifferentiated nasopharyngeal carcinoma. Duran et al[@b33-ott-10-2155] also performed a retrospective study that included 240 lung adenocarcinoma patients. They concluded that low levels of AGR remained an independent factor of mortality. In colorectal cancer, Azab et al[@b16-ott-10-2155] got a similar result. However, studies about the association between AGR and the prognosis of gastric cancer have not been performed.

In the present study, we first discovered that pretreatment AGR value can predict the prognosis of gastric cancer patients. Furthermore, lower level of AGR is found to be an effective factor in predicting worse survival.

The AGR has an advantage over a single value of just albumin or globulin in predicting prognosis. The reasons are as follows. First, AGR is a biochemistry index combined by two effective indicators, albumin and globulin; it would work better than just one of them. Second, as both of them are mainly produced by the liver, factors such as hepatic dysfunction, raw materials insufficient, and imbalance of internal environment will influence their level. Finally, the AGR test is more comprehensive and more effective to most of the primarily diagnosed patients, and it is much more accurate compared with the former (albumin or globulin alone).

On the other hand, there is still no unified method to assess the optimal cutoff points for the expression of AGR. Several methods have been applied to discover the best cutoff points. Azab et al[@b34-ott-10-2155] defined the cutoff value by dividing the population into equal quartiles. In their study, patients were divided into equal tertiles according to the 33rd and 66th AGR percentile. Yao et al[@b35-ott-10-2155] stratified globulin to albumin ratio using the receiver operating characteristics curve, and the optimal cutoff point was defined as the value at the largest Youden index.

In the present study, we defined the cutoff values using the software X-tile, in which X-plots were produced to evaluate the level of AGR based on outcome. Actually, X-tile could act as a comprehensive evaluation of all candidate methods based on the expression level of biomarkers. It could also offer a way to divide the population into training set and validation set. Similarly, using X-tile, Xu et al[@b36-ott-10-2155] also determined the optimal cutoff points for PEBP1 protein levels and mRNA levels effectively and precisely.

As far as we know, the association between AGR and the prognosis of gastric cancer was first put forward in our study, which indicate that AGR should be an independent and significant factor in the diagnosis, treatment, and prediction of gastric cancer. In terms of safety and comfort, AGR measurement has the edge on other factors because it is noninvasive and it is more accurate and effective to the patients. In spite of this, further prospective studies are still needed before the clinical application of AGR.

**Disclosure**

The authors report no conflicts of interest in this work.

![X-Tile analysis of prognosis based on AGR groups; X-tile plots showing overall survival in different AGR groups.\
**Abbreviation:** AGR, albumin--globulin ratio.](ott-10-2155Fig1){#f1-ott-10-2155}

![Kaplan--Meier analyses of overall survival.\
**Notes:** Survival analyses of total population stratified by AGR groups (**A**). Post-6-month survival according to AGR groups (**B**). Survival analyses of study patients (serum albumin ≥35 g/L) by AGR groups (**C**).\
**Abbreviation:** AGR, albumin--globulin ratio.](ott-10-2155Fig2){#f2-ott-10-2155}

![Kaplan--Meier analyses of overall survival according to the level of globulin (g/L).\
**Notes:** Survival analyses of total population stratified by globulin groups (**A**). Survival analyses of study patients (serum albumin ≥35 g/L) by globulin groups (**B**).](ott-10-2155Fig3){#f3-ott-10-2155}

###### 

Baseline characteristics of 507 gastric cancer patients stratified by pretreatment AGR groups

  Variable                        Lower AGR group AGR \<1.93   Higher AGR group AGR ≥1.93   *P*-value
  ------------------------------- ---------------------------- ---------------------------- -----------
  Total study                     440                          67                           
  Age (years)                                                                               
   \<60/≥60                       214/226                      40/27                        \<0.001
  Gender (male/female)            290/150                      58/9                         0.001
  Differentiated type                                                                       
   Well/moderate and poor         82/358                       18/49                        0.005
  Tumor size                                                                                
   (\<6 cm/≥6 cm)                 70/370                       65/2                         0.057
  Location (upper/middle/lower)   216/73/151                   30/7/30                      0.178
  T stage (T1/T2/T3/T4)           36/33/103/268                10/5/7/45                    0.015
  Node stage (N0/N1/N2/N3)        107/48/85/200                21/11/11/24                  0.294
  AJCC stage (I/II/III)           47/89/304                    12/12/43                     0.014
  Total protein (g/L)             66.9±7.1                     62.8±5.3                     0.010
  Albumin (g/L)                   39.8±4.7                     42.7±3.5                     0.012
  Globulin (g/L)                  26.8±4.2                     20.7±2.9                     \<0.001
  Blood platelet                  257.5±102.0                  230.0±68.2                   0.014
  White blood cell (×10^9^/L)     7.0±2.7                      6.8±2.8                      0.520
  Neutrophil (×10^9^/L)           4.4±2.5                      4.3±2.6                      0.889
  Lymphocyte (×10^9^/L)           1.9±0.7                      1.9±0.6                      0.068
  Hemoglobin (g/L)                121.0±23.7                   130.6±22.7                   0.475
  C-reactive protein (mg/L)       12.7±31.3                    5.93±23.4                    0.013

**Note:** The continuous variables were presented as mean ± SD and categorical variables were presented as frequency.

**Abbreviations:** AGR, albumin--globulin ratio; AJCC, American Joint Committee on Cancer; SD, standard deviation.

###### 

Hazard ratios of baseline characteristics for all-cause mortality in gastric cancer patients (univariate analysis)

  Variable                                       Hazard ratio (95% CI)    *P*-value[a](#tfn3-ott-10-2155){ref-type="table-fn"}
  ---------------------------------------------- ------------------------ ------------------------------------------------------
  Age (≥60/\<60 years)                           1.020 (1.010--1.029)     \<0.001
  Sex (male/female)                              0.922 (0.780--1.263)     0.950
  Tumor size (≥6 cm/\<6 cm)                      2.571 (1.772--3.730)     \<0.001
  Differentiated type (well/moderate and poor)   0.900 (0.681--1.189)     0.458
  Location (ref: lower)                                                   
   Upper                                         2.148 (1.652--2.793)     \<0.001
   Middle                                        1.519 (1.016--2.175)     0.023
  T stage (ref: T1)                                                       
   T2                                            2.599 (1.037--6.515)     0.042
   T3                                            6.887 (3.163--14.995)    \<0.001
   T4 (a/b)                                      7.420 (3.491--15.770)    \<0.001
  Node stage (ref: N0)                                                    
   N1                                            2.564 (1.563--4.206)     \<0.001
   N2                                            3.927 (2.576--5.987)     \<0.001
   N3                                            6.548 (4.496--9.538)     \<0.001
  AJCC stage (ref: I)                                                     
   Stage II                                      4.831 (2.051--11.382)    \<0.001
   Stage III                                     14.393 (6.394--32.401)   \<0.001
  Total protein (g/L)                            0.991 (0.974--1.007)     0.267
  Albumin (g/L)                                  0.959 (0.937--0.982)     \<0.001
  Globulin (g/L)                                 1.011 (0.987--1.035)     0.380
  White blood cell (×10^9^/L)                    1.061 (1.019--1.104)     0.004
  Blood platelet (×10^9^/L)                      1.000 (0.999--1.001)     0.801
  Neutrophil (×10^9^/L)                          1.099 (1.056--1.144)     \<0.001
  Lymphocyte (×10^9^/L)                          0.743 (0.626--0.882)     0.001
  Hemoglobin (g/L)                               0.998 (0.994--1.003)     0.492
  C-reactive protein (mg/L)                      1.010 (1.007--1.013)     \<0.001
  AGR (\<1.93/≥1.93)                             1.755 (1.204--2.559)     0.003

**Note:**

Log-rank test.

**Abbreviations:** AGR, albumin--globulin ratio; AJCC, American Joint Committee on Cancer; CI, confidence interval.

###### 

Hazard ratios for all-cause mortality in gastric cancer patients (multivariate analysis)

  Variable                 Hazard ratio (95% CI)   *P*-value[a](#tfn5-ott-10-2155){ref-type="table-fn"}
  ------------------------ ----------------------- ------------------------------------------------------
  Model 1                                          
   Age (≥60/\<60 years)    1.259 (1.038--1.527)    0.02
  Location (ref: lower)                            
   Upper                   1.293 (1.036--1.613)    0.023
   Middle                  1.251 (0.935--1.673)    0.131
  AJCC stage (ref: I)                              
   Stage II                1.704 (1.114--2.608)    0.014
   Stage III               3.796 (2.587--5.569)    \<0.001
   NLR (per unit)          1.062 (1.032--1.094)    \<0.001
   AGR (\<1.93 vs ≥1.93)   1.374 (1.020--1.851)    0.037
  Model 2                                          
   Age (\<60/≥60 years)    1.568 (1.237--1.988)    \<0.001
  Location (ref: lower)                            
   Upper                   1.589 (1.206--2.093)    0.001
   Middle                  1.305 (0.902--1.887)    0.158
  Node stage (ref: N0)                             
   N1                      2.183 (1.299--3.668)    0.003
   N2                      2.837 (1.803--4.465)    \<0.001
   N3                      5.246 (3.479--7.909)    \<0.001
  T stage (ref: T1)                                
   T2                      1.422 (0.517--2.908)    0.495
   T3                      2.661 (1.114--6.306)    0.028
   T4 (a/b)                2.877 (1.229--6.735)    0.015
   NLR (per unit)          1.072 (1.040--1.104)    \<0.001
   AGR (\<1.93/≥1.93)      1.489 (1.004--2.208)    0.048

**Note:**

Cox proportional hazards model.

**Abbreviations:** AGR, albumin--globulin ratio; NLR, neutrophil--lymphocyte ratio; AJCC, American Joint Committee on Cancer; CI, confidence interval.
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